In addition, GWAS fine mapping identified potential causal variants in GATAD2A, SUGP1, and MAU2, while TWAS fine mapping implicated SAMM50 as a driver of steatosis in normal-weight individuals, possibly through changes in gene expression. The gene discussed is MAU2; the disease is steatosis.